Logo

HLN

Haleon plc

HLN

Haleon plc • NYSE
$9.78 ▲ 0.20% (+0.02)
Market Cap $44.31 B
52w High $11.42
52w Low $8.71
Dividend Yield 0.18%
P/E 22.23
Volume 4.52M
Outstanding Shares 4.53B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $5.48B ▲ $2.332B ▲ $806M ▲ 14.708% $0.18 ▲ $1.393B ▲
Q2-2025 $2.74B $1.166B $403M 14.708% $0.089 $696.5M
Q1-2025 $2.74B ▼ $1.166B ▼ $403M ▼ 14.708% ▲ $0.089 ▼ $696.5M ▼
Q4-2024 $5.539B ▲ $2.345B ▲ $716M ▲ 12.927% ▼ $0.16 ▲ $1.264B ▲
Q3-2024 $2.78B $1.043B $485M 17.446% $0.11 $752.75M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $676M $31.828B $15.83B $15.941B
Q1-2025 $676M ▼ $31.828B ▼ $15.83B ▼ $15.941B ▼
Q4-2024 $2.25B ▲ $34.315B ▲ $18.091B ▲ $16.166B ▼
Q3-2024 $531M $0 ▼ $-16.707B ▼ $16.707B ▲
Q2-2024 $531M $33.396B $16.689B $16.6B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $806M ▲ $1.027B ▲ $-76M ▼ $-2.517B ▼ $0 $931M ▲
Q2-2025 $403M $513.5M $-38M $-1.258B $0 $465.5M
Q1-2025 $403M ▼ $513.5M ▲ $-38M ▼ $-1.258B ▼ $0 $465.5M ▲
Q4-2024 $716M ▲ $0 $0 $0 $0 $0
Q3-2024 $485M $0 $0 $0 $0 $0

Revenue by Products

Product Q2-2023
Respiratory Health
Respiratory Health
 $840.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Haleon’s revenue has grown steadily but not dramatically, showing a pattern of slow, dependable expansion rather than rapid acceleration. Profitability has improved over time: gross profit and operating profit have both edged higher, suggesting good pricing power and cost control in its core categories. The bottom line dipped around the time of the spin-off but has since recovered, indicating that one-off separation and financing effects were a drag that is now easing. Overall, the income statement reflects a mature consumer health business with stable sales, gradually improving margins, and earnings that are trending in the right direction, even if growth is not fast.

Balance Sheet

Balance Sheet The balance sheet shows a large and stable asset base, which fits a global consumer health leader. Debt jumped sharply when Haleon became an independent company and remains meaningful, while shareholder equity dropped at the same time, so the business is more leveraged than before the spin-off. Since then, debt has started to edge down and cash on hand has risen, which slightly improves financial flexibility but doesn’t remove leverage risk. In simple terms, Haleon is solidly asset-backed, but its capital structure relies heavily on borrowing, making ongoing debt management and refinancing terms important watchpoints.

Cash Flow

Cash Flow Cash generation is a clear strength. Operating cash flow has improved over several years, and free cash flow remains comfortably positive even after regular investment in the business. Capital spending needs are modest relative to cash generated, which leaves room for debt reduction, dividends, or other uses, depending on management priorities. The pattern here is of a cash-generative, consumer-branded business whose everyday operations throw off reliable cash, a helpful counterbalance to its higher debt load.

Competitive Edge

Competitive Edge Haleon benefits from a portfolio of well-known consumer health brands that people buy repeatedly, often on habit and trust, which is a powerful advantage. Many of its products hold leading positions in their categories, supported by strong relationships with pharmacists, dentists, and other health professionals who recommend them. Its global distribution reach and scale help it get shelf space and negotiate effectively with retailers around the world. The main challenges come from intense competition with other global consumer and pharma companies, private-label alternatives, and shifting consumer preferences, but Haleon’s brand equity and reach give it a sturdy competitive footing.

Innovation and R&D

Innovation and R&D The company invests consistently in research and development, especially in oral care, pain relief, and vitamins and supplements, where science and differentiation really matter. Recent launches such as advanced Sensodyne variants, new nasal technologies, and a topical over-the-counter erectile dysfunction treatment show it can bring genuinely new products to regulated markets, not just minor line extensions. Haleon is also pushing digital capabilities in its supply chain and exploring areas like digital health, personalized nutrition, and more sustainable products, which could support future premium offerings and consumer loyalty. The opportunity is to keep turning this steady R&D spend into visible, category-shaping innovations; the risk is that if innovation slows or misses consumer trends, growth could stay modest despite the investment.

Summary

Haleon looks like a classic global consumer health company: slow but steady revenue growth, improving profitability, and strong, recurring cash flows backed by trusted brands. The main financial trade-off is between its robust cash generation and stable asset base on one side, and a relatively high level of debt created around the spin-off on the other. Competitively, its brand strength, professional endorsements, and distribution scale provide a meaningful moat, reinforced by ongoing science-based innovation rather than short-lived fads. Looking ahead, the key themes to watch are its ability to gradually accelerate growth within core categories, continue reducing leverage, and maintain a healthy pipeline of consumer-relevant innovations while navigating regulatory and competitive pressures.

NEWS

October 8, 2025 · 8:07 AM UTC

Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI

Read more